Results 141 to 150 of about 34,850 (241)

Efficacy and Safety of Closure‐Focused Anti‐Reflux Mucoplasty Compared With Conventional ARMS: A Propensity Score–Matched Study (With Video)

open access: yesDigestive Endoscopy, Volume 38, Issue 6, June 2026.
ABSTRACT Background Endoscopic anti‐reflux therapies, including anti‐reflux mucosectomy (ARMS) and mucosal ablation (ARMA), offer minimally invasive treatment for gastroesophageal reflux disease (GERD) but carry risks of stenosis and delayed bleeding.
Kazuki Yamamoto   +9 more
wiley   +1 more source

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5163-5173, June 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used for the treatment of type 2 diabetes, yet their downstream consequences in routine clinical practice remain incompletely characterized.
Yazan Alhamdan   +2 more
wiley   +1 more source

Genetic Determinants of Peanut‐Specific IgG4 Levels in the Context of Sustained Oral Peanut Exposure in the LEAP Study

open access: yesImmunology, Volume 178, Issue 2, Page 280-292, June 2026.
A cumulative genetic score based on IgG4‐associated variants explains a substantial proportion of variance in psIgG4 levels during sustained peanut consumption, highlighting strong gene‐by‐environment interactions. Our findings suggest that early, sustained peanut consumption, in combination with genetic factors, promotes a protective immune response ...
Kanika Kanchan   +14 more
wiley   +1 more source

Rationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations

open access: yesJournal of Gastroenterology and Hepatology, Volume 41, Issue 6, Page 1685-1700, June 2026.
ABSTRACT Background and Aim Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations ...
Somchai Leelakusolvong   +13 more
wiley   +1 more source

Poliprotect in the PPI Deprescription Phase of Endoscopy‐Negative Heartburn and Epigastric Pain Syndrome Patients: An RCT Post Hoc Analysis

open access: yesNeurogastroenterology &Motility, Volume 38, Issue 6, June 2026.
Deprescribing PPIs is often difficult because of symptom recurrence and rebound acid hypersecretion, and evidence supporting effective deprescribing strategies is scarce. This post hoc analysis shows that on‐demand Poliprotect is a safe and potentially effective strategy to maintain or improve symptom control in non‐erosive reflux and epigastric pain ...
Enrico Stefano Corazziari   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy